Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis

PHASE3CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

June 10, 2015

Primary Completion Date

March 15, 2017

Study Completion Date

March 15, 2017

Conditions
Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions
DRUG

Cinacalcet

Cinacalcet was provided as 5 mg capsules for sprinkling or as 30 mg film-coated tablets for swallowing. The protocol-specified doses were: 1, 2.5, 5, 7.5, 10, 15, 30, 60, 90, 120, and 180 mg.

Trial Locations (33)

1020

Research Site, Brussels

6720

Research Site, Szeged

10029

Research Site, New York

11527

Research Site, Athens

16147

Research Site, Genova

21287

Research Site, Baltimore

27834

Research Site, Greenville

30084

Research Site, Tucker

30625

Research Site, Hanover

35043

Research Site, Marburg

39216

Research Site, Jackson

43205

Research Site, Columbus

44195

Research Site, Cleveland

45229

Research Site, Cincinnati

55454

Research Site, Minneapolis

63110

Research Site, St Louis

64108

Research Site, Kansas City

69120

Research Site, Heidelberg

73104

Research Site, Oklahoma City

75015

Research Site, Paris

75235

Research Site, Dallas

77030

Research Site, Houston

84113

Research Site, Salt Lake City

90027

Research Site, Los Angeles

107014

Research Site, Moscow

198205

Research Site, Saint Petersburg

443095

Research Site, Samara

02115

Research Site, Boston

07052

Research Site, West Orange

150 06

Research Site, Prague

30-663

Research Site, Krakow

93-338

Research Site, Lodz

01135

Research Site, Kyiv

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY